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Metabolism of the new liposomal anticancer drug
N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice
Abstract
Metabolism and excretion of the new antitumor drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine
(NOAC) was investigated in mice. Mice were injected i.v. with tritium-labeled liposomal NOAC (4
micromol/mouse). Analysis of HPLC-purified extracts of liver homogenates by liquid chromatography
coupled with mass spectrometry revealed only the presence of unmetabolized drug. To study the
excretion of the administered drug, mice were injected with tritium-labeled liposomal NOAC or as
comparison with 1-beta-D-arabinofuranosylcytosine (ara-C; 4 micromol/mouse) and housed up to 48 h
in metabolic cages. Urine and feces were collected at different time points and the kinetics of excreted
radioactivity were determined. After 48 h, 39% of the injected [5-3H]NOAC radioactivity was excreted
in urine and 16% in feces, whereas ara-C radioactivity was only found in urine with 48% of the injected
dose. Feces extracts and urine were purified by HPLC and radioactive fractions were further analyzed
by liquid chromatography coupled with mass spectrometry. The radioactivity of feces extracts of
NOAC-treated mice was composed of unmetabolized NOAC, hydroxylated NOAC (NOAC + OH), its
sulfated derivative (NOAC + OSO3H), and unidentified metabolites, whereas in urine, the hydrophilic
molecules ara-C and ara-U were found. During the period of 48 h only 2% of the injected NOAC was
eliminated in its unmetabolized form, whereas 25% was identified as main metabolite ara-C. Urine
collected during 48 h in ara-C-treated mice contained 33% of the injected dose as unmetabolized drug
and 13% as the main metabolite ara-U. Thus, NOAC is metabolized by two major pathways, one
leading to the hydrophilic metabolites ara-C and ara-U and the other to hydroxylated and sulfated
NOAC.
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ABSTRACT:
Metabolism and excretion of the new antitumor drug N4-octadecyl-
1-b-D-arabinofuranosylcytosine (NOAC) was investigated in mice.
Mice were injected i.v. with tritium-labeled liposomal NOAC (4
mmol/mouse). Analysis of HPLC-purified extracts of liver homog-
enates by liquid chromatography coupled with mass spectrometry
revealed only the presence of unmetabolized drug. To study the
excretion of the administered drug, mice were injected with triti-
um-labeled liposomal NOAC or as comparison with 1-b-D-arabino-
furanosylcytosine (ara-C; 4 mmol/mouse) and housed up to 48 h in
metabolic cages. Urine and feces were collected at different time
points and the kinetics of excreted radioactivity were determined.
After 48 h, 39% of the injected [5-3H]NOAC radioactivity was ex-
creted in urine and 16% in feces, whereas ara-C radioactivity was
only found in urine with 48% of the injected dose. Feces extracts
and urine were purified by HPLC and radioactive fractions were
further analyzed by liquid chromatography coupled with mass
spectrometry. The radioactivity of feces extracts of NOAC-treated
mice was composed of unmetabolized NOAC, hydroxylated NOAC
(NOAC 1 OH), its sulfated derivative (NOAC 1 OSO3H), and un-
identified metabolites, whereas in urine, the hydrophilic molecules
ara-C and ara-U were found. During the period of 48 h only 2% of
the injected NOAC was eliminated in its unmetabolized form,
whereas 25% was identified as main metabolite ara-C. Urine col-
lected during 48 h in ara-C-treated mice contained 33% of the
injected dose as unmetabolized drug and 13% as the main metab-
olite ara-U. Thus, NOAC is metabolized by two major pathways,
one leading to the hydrophilic metabolites ara-C and ara-U and the
other to hydroxylated and sulfated NOAC.
Acute myelogenous leukemia can be effectively treated with 1-b-
D-arabinofuranosylcytosine (ara-C)1 (Keating et al., 1982; Gahrton,
1983; Plunkett and Gandhi, 1993). However, its usefulness is limited
by its rapid deamination to the biologically inactive metabolite 1-b-
D-arabinofuranosyluracil (ara-U) (Ho and Frei, 1971). To protect the
drug from deamination, a large number of chemical modifications of
ara-C were made in the past (Wempen et al., 1968; Kanai and Ichino,
1974; Rosowsky et al., 1982). Aoshima and coworkers (1976) ob-
served enhanced cytotoxicity after modifying the N4-amino group
with hexadecyl (C16) to behenoyl (C22) fatty acids, whereas acyl
modifications with longer or shorter chains did not influence the drug
effect compared with ara-C. Structure-activity relationships were also
reported for alkyl-ara-C derivatives (Schwendener et al., 1995b). The
alkyl modification of ara-C is not susceptible to hydrolysis and
therefore more stable than the acyl compounds (Tsuruo et al., 1982).
The new derivative N4-octadecyl-1-b-D-arabinofuranocylcytosine
(NOAC; Fig. 6) is insignificantly deaminated to ara-U after incubation
with human serum or mouse liver microsomes (Schwendener et al.,
1995a). The long-chain alkyl-derivatives of ara-C are highly lipophilic
without amphiphilic properties and therefore exert no hemolytic tox-
icity (Koller-Lucae et al., 1997). This is a further advantage compared
with the acyl-derivatives. Pharmacological in vitro studies with N4-
hexadecyl-1-b-D-arabinofuranocylcytosine (NHAC) or NOAC sug-
gest mechanisms of action that are different from ara-C. Cell uptake
is nucleoside transporter independent, followed by an ara-C-59-
triphosphate formation, which seems to be too low (2.5- to 150-fold
lower as compared with ara-C) to contribute to the cytotoxicity of
NHAC. Apoptosis of tumor cells was only induced at NHAC con-
centrations 20 times higher than observed for ara-C (Horber et al.,
1995a,b,c). In human tumor xenografts in nude mice, NOAC showed
a significantly better effect than ara-C in various leukemias, and an
impressive antitumor activity against different solid tumors (Schwen-
dener et al., 1995a). Other lipophilic ara-C derivatives such as ara-C-
59diphosphate-b-palmitoyl-DL-thiobatyl alcohol and ara-C-59-diphos-
phate-L-dipalmitin showed activity against solid tumors (Berdel et al.,
1989). Interestingly, NOAC is also active after oral administration
(Schwendener et al., 1996) as are the lipophilic ara-C derivatives
N4-palmitoyl-1-b-D-arabinofuranosylcytosine (Ohno et al., 1987), N4-
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stearoyl-1-b-D-arabinofuranosylcyosine (Aoshima et al., 1976), and
1-b-D-arabinofuranosylcytosine-59-stearylphosphate (Kodama et al.,
1989; Ueda et al., 1994). Pharmacokinetic analysis of NOAC in mice
gave parameters typical for a lipophilic drug, with distribution into
deeper compartments, leading to a prolonged circulation and therefore
an elimination half-life of 7 h (Koller-Lucae et al., 1997). In an
ongoing phase I study that we are performing with liposomal NOAC
at the University Hospital Zurich, the plasma elimination half-life of
NOAC given as i.v. infusion, as determined by HPLC, ranged be-
tween 11 to 16 h (Koller-Lucae et al., 1997). Schleyer et al. (1995)
observed a comparable elimination half-life of 9 h for the lipophilic
ara-C derivative 1-b-D-arabinofuranosylcytosine-59-stearylphosphate
in humans.
NOAC is a good candidate for cancer therapy with potential ad-
vantages compared with the related drug ara-C and to other lipophilic
ara-C derivatives. In this study we addressed the question whether
NOAC is metabolized by v- and b-oxidation of the side chain as
reported for the lipophilic compounds 1-b-D-arabinofuranosylcy-
tosine-59-stearylphosphate (Yoshida et al., 1990) and N4-behenoyl-1-
b-D-arabinofuranosylcytosine (Oh-Ishi et al., 1981), or whether
NOAC could also be metabolized to ara-C.
Liver homogenates of mice treated with tritium-labeled NOAC
were purified by HPLC and pools containing radioactivity were
analyzed by liquid chromatography-mass spectrometry (LC/MS). Fur-
thermore, the excretion kinetics of NOAC or ara-C in urine and feces
were analyzed. Unmetabolized drug and metabolites were identified
from purified feces extracts and in urine by LC/MS.
Materials and Methods
Chemicals. NOAC (Fig. 6), NHAC, and N4-hexyl-1-b-D-arabinofuranocyl-
cytosine were synthesized as described before (Schott et al., 1994; Schwen-
dener et al., 1995a). Soy phosphatidylcholine was obtained from L. Meyer
(Hamburg, Germany). Cholesterol (Fluka AG, Buchs, Switzerland) was re-
crystallized from methanol. Tetrahydrouridine (THU) was from the Drug
Synthesis and Chemistry Branch, Developmental Therapeutics Program, Di-
vision of Cancer Treatment, National Cancer Institute (Rockville, MD). THU
solution was obtained by dissolving 1 mg/ml in PBS (THU/PBS). DL-a-
Tocopherol, all buffer salts, and other chemicals used were either analytical or
HPLC grade and were obtained from Merck (Darmstadt, Germany) Fluka, or
Scharlau (Barcelona, Spain). Soluene 350 and Ultima Gold scintillation cock-
tail were from Packard Instruments (Groningen, the Netherlands). Ara-C and
NOAC were tritium labeled (1.11 TBq/mmol [5-3H]ara-C and 0.370 GBq/
mmol [5-3H]NOAC) by Amersham Int. (Little Chalfont, UK).
Preparation of Liposomes. Small (80–90 nm) unilamellar liposomes were
prepared in PBS (pH 7.4) by sequential filter extrusion as described previously
(Koller-Lucae et al., 1997). Liposome size and homogeneity were determined
by laser light scattering (Submicron Particle Sizer model 370; Nicomp, Santa
Barbara, CA). The basic composition of the liposomes used was 100 mM soy
phosphatidylcholine, 20 mM cholesterol, 0.9 mM DL-a-tocopherol, and 20 mM
NOAC. For control experiments, 20 mM ara-C was dissolved in PBS. All
preparations were trace labeled with [5-3H]NOAC or [5-3H]ara-C, respec-
tively, sterile filtrated (0.2 mm, Schleicher & Schuell, Feldbach, Switzerland),
and used within 2 days.
Liver Metabolism of NOAC. As outlined in the scheme of Fig. 1, which
summarizes the methods used for the analysis of the metabolites, mice (pairs
of 2 female ICR, 22 6 1 g) were injected into the tail vein, each with 4 mmol
NOAC in liposomes. After ½, 1, 2, and 4 h, the animals were sacrificed by
ether anesthesia. Blood was collected by cardiac puncture and the liver
perfused with 10 ml THU/PBS. The livers without the gall bladder were
removed and stored in THU/PBS at 220°C until further analysis. Before
scintillation counting, the whole blood was digested with 2 ml Soluene 350,
bleached with peroxide 30% (w/w), and neutralized with concentrated hydro-
chloric acid (Koller-Lucae et al., 1997). Livers were homogenized in 3 ml
THU/PBS (Dounce homogenizer, B. Braun, Melsungen, Germany) and for
total radioactivity aliquots of 20 ml were digested with 0.2 ml Soluene 350 and
neutralized with concentrated hydrochloric acid before scintillation counting.
Then the homogenates were ultracentrifuged (1 h, 100,000g, 10°C, SW 40 Ti
rotor, Beckman ultracentrifuge; Beckman Instruments, Fullerton, CA). The
supernatant containing the cytosol was removed and the remaining pellet with
membranes, nuclei, microsomes, and mitochondria extracted with 6 to 8 ml
methanol at room temperature in a bath sonicator (Branson, Danbury, CT) for
1 h followed by centrifugation (10 min, 800g, 20°C). Aliquots of the cytosol
and methanolic extracts were counted directly for tritium activity in a Tri-Carb
Liquid Scintillation Analyzer (Packard Instruments). Aliquots of resuspended
pellets were digested as described above. As a control, the liver of an untreated
mouse was processed identically.
Urine and Feces. Groups of three mice (female ICR, 22–26 g) were housed
in metabolic cages (Tecniplast, Buguggiate, Italy) with free access to food and
water. After a 24-h adaptation, they were injected in the tail vein with a volume
of 200 ml containing 4 mmol liposomal NOAC or ara-C dissolved in PBS (see
Fig. 1). Three cages were run in parallel. Urine and feces were collected in
separate tubes. To prevent deamination of ara-C, 0.5 ml THU/PBS was added
to the urine collecting tubes. The tubes were exchanged after the adaptation
period and 4, 8, 24, and 48 h after drug injection. The mice were transferred
every 24 h into clean metabolic cages to record the differences of food and
water intake and amounts of excrements produced before and after treatment.
The samples from the adaptation period were used as untreated controls.
Before scintillation counting, feces were extracted by sonication for 1 h once
in a volume of 10 ml PBS and twice in an equal volume of methanol as
described above. The aqueous and methanolic extracts were analyzed sepa-
rately. Supernatants and urine were measured directly, whereas aliquots of the
remaining pellet were digested in 2 ml Soluene 350 and prepared for counting
as described before. Values are calculated as percentage of injected radioac-
tivity. Data were fitted with a hyperbolic equation to calculate saturation.
FIG. 1. Purification scheme for liver, urine, and feces of NOAC- or ara-C-
treated mice.
Radioactivity was determined in samples indicated with an asterisk.
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HPLC. Method a. Urine, the PBS, and methanolic extracts of feces, as well
as liver cytosol and the methanolic liver extracts of treated and untreated mice
of all time points, were analyzed with the HPLC method a (Rentsch et al.,
1995) consisting of a 9010 pump, a 9100 autosampler, a 9050 UV-Vis-detector
(Varian, Sunnyvale, CA), and a column-heater Croco-cil (Cluzean-infolabo
SA, Saint-Foy-la-Grande, France). The detector was set at 275 nm and the
autosampler was equipped with a 92-ml loop. Two identical columns were
connected in series (Nucleosil C18, 5-mm particle size, 120 Å pore size, 250 3
4 mm i.d.) and protected with a guard column (11 3 4 mm) packed with the
same material. The first column was kept at room temperature, and the second
at 45°C. Isocratic elution was performed with methanol containing 10% (v/v)
of 0.16 M ammonium formate buffer, pH 2.7. The flow rate was 0.9 ml/min
and fractions of 0.9 ml were collected with a LKB SuperRac fraction collector
(Bromma, Sweden). The radioactivity of collected fractions was determined.
Representative HPLC chromatograms are shown in Figs. 2 and 4. To quantify
metabolites and unmetabolized excreted drug, corresponding fractions were
pooled for each extract and cumulated over 48 h. Pools I, II, and III eluted with
retention times Rt of 4 to 6 min, 8 to 10 min, and 21 to 23 min, respectively.
To augment the concentration of the metabolites in the pools, the samples
for LC/MS were processed as follows. Urine and feces of NOAC-treated mice
collected between 8 and 24 h and urine of ara-C-treated mice collected
between 4 and 8 h were chosen, as well as methanolic liver extracts of mice
that were sacrificed 60 min after treatment. As controls, urine and feces of
mice collected during their 24-h adaptation period to metabolic cages and a
liver extract of an untreated mouse were used. Of each chosen sample, four
independent runs on HPLC method a were collected and pooled (pools I, II,
and III) for each sample as described above. These pooled extracts were
evaporated to dryness with a Rotavapor instrument (Buechi, Flawil, Switzer-
land), dissolved in 0.15 ml methanol and re-chromatographed for further
purification using HPLC method a. These pools were evaporated to dryness
and stored at 220°C until LC/MS analysis.
Method b. To distinguish ara-C from ara-U in urine of NOAC- as well as of
ara-C-treated mice, the corresponding extracts and untreated controls (Fig. 1)
were chromatographed on HPLC system b for LC/MS analysis. Samples were
injected four times (100-ml loop) on the HPLC system, which consisted of a
2150 pump and a 2152 controller; absorption was monitored online at 279 nm
with a 2238 UV-monitor (LKB). An Ultracarb 7 ODS-30 column protected
with a guard column packed with the same material (Phenomenex 30 3 3.2 1
250 3 3.2 mm; Phenomenex, Torrance, CA) was run with ammonium acetate
buffer 0.01 M, pH 7, as mobile phase and a flow rate of 0.35 ml/min. Fractions
of 0.35 ml were collected with a SuperRac fraction collector (LKB).
Aliquots of 20 ml from all collected fractions were measured for radioac-
tivity. Fractions containing high levels of radioactivity (Rt 4–5 min and 5–8
min) were lyophilized and stored at 220°C until LC/MS analysis. The THU/
PBS extract of feces from a NOAC-treated mouse was also purified with
HPLC method b.
Method c. HPLC method c was operated on a HP Series 1100 instrument
(Hewlett Packard Schweiz AG, Urdorf, Switzerland). Chromatography was
performed on an Ultracarb 5 column (150 3 1.0 mm; Phenomenex) with a
binary mixture of 0.05% (v/v) trifluoroacetic acid (TFA) in water (solvent A)
and methanol/THU/TFA at 90:10:0.05% (v/v) (solvent B). The mobile phase
was initially composed of 90% solvent A and 10% solvent B for 7 min. It was
then linearly changed to 100% solvent B within 18 min and held isocratic for
20 min and programmed to return to starting conditions within 5 min. The flow
rate was 0.1 ml/min and the injection volume 5 ml (Breithaupt and Schick,
1981). UV absorption was monitored online at 270 nm before entering the MS.
LC/MS. LC/MS samples chromatographed with HPLC method a were
dissolved as follows. Urine, feces (pool I), N4-hexyl-1-b-D-arabinofuranocyl-
cytosine, ara-U, and ara-C standards in solvent A of HPLC method c. Pool II,
pool III, NHAC, and NOAC standards in solvent B of HPLC method c. The
samples were dissolved in a volume of 0.25 ml and the reference compounds
were dissolved at 0.2 mg/ml. Analyses were performed with HPLC method c
on a Platform LC mass spectrometer (Micromass, Manchester, UK). For the
detection of negative ions, the mobile phase of the HPLC method c was run
without TFA. Samples were monitored under positive (1ESI) or negative
(2ESI) electrospray ionization conditions with full scan from m/z 50 to 1000,
a scan time of 1 s/scan, and a cone voltage of either 42 or 100 V. The needle
potential was set to 4.23 kV. Calibration and sensitivity tests were performed
with CsI for 1ESI and NaNO3 for 2ESI.
To detect ara-C or ara-U in urine of treated mice the prepared fractions (Rt
4–5 min and 5–8 min) from HPLC method b were dissolved in 0.05 ml
(NOAC mice) or 0.25 ml (ara-C mice) ammonium acetate buffer (0.01 M, pH
7). The fraction (Rt 4–5 min) of the THU/PBS extract of feces from a NOAC-
treated mouse and controls were treated alike. Ara-C and ara-U standards were
dissolved in ammonium acetate buffer to 0.2 mg/ml. The LC/MS system was
run using the HPLC system b, which contained no TFA in the mobile phase.
Therefore, 1% (v/v) TFA in methanol was added to the eluent after the column
at 0.035 ml/min to enhance the formation of positive ions, using a Harvard
syringe pump model 22 (Harvard Instruments, Gams, Switzerland) equipped
with a gas-tight syringe (Hamilton, Reno, NV). Full-scan 1ESI spectra were
acquired from m/z 100 to 300 at 1 s/scan, a low cone voltage of 15 V, or a high
cone voltage of 42 V, and a needle potential of 3.00 kV. All LC/MS analyses
were scanned for mass spectra differing from untreated controls.
FIG. 3. Cumulative excretion of radioactivity over 48 h from NOAC- or ara-C-
treated mice.
Data were fit with hyperbolas with correlation coefficients r for NOAC urine,
NOAC feces, and ara-C urine of 0.98, 0.97, and 0.89, respectively.
FIG. 2. Representative HPLC chromatogram (method a) of a liver extract from
NOAC-treated mice 60 min after i.v. injection.
NOAC was identified in pool III by LC/MS.
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Results
Liver. NOAC (4 mmol)-treated mice were sacrificed at different
time points. The blood and liver concentration versus time curves
(data not shown) were comparable with earlier experiments (Koller-
Lucae et al., 1997). Peak concentration in the liver was found to be
35% of the applied radioactivity 1 h after injection. Cytosol was
isolated from homogenized livers by ultracentrifugation and the pellet
was extracted with methanol as outlined in Fig. 1. The measured ratio
of cytosol radioactivity to total liver radioactivity was 1:14 for all time
points. Cytosol and methanolic fractions were analyzed by HPLC
method a. In all samples, radioactivity was only detected at the Rt of
21 to 23 min, typical for the retention of NOAC. A representative
chromatogram of a liver extract from NOAC-treated mice 60 min
after i.v. injection is presented in Fig. 2.
Excretion in Urine and Feces. Mice were injected with 4 mmol
NOAC or ara-C i.v. and excretion was monitored at different time
points (Fig. 3). Toxic effects were not observed after injection of 15%
of the LD50 of NOAC (Schwendener et al., 1995a). No difference in
volume and weight of excrements, food intake, or body weight be-
tween treated and untreated animals was detected when comparing the
24-h collection intervals. As summarized in Table 1, 55 6 2% of the
injected dose per mouse were cumulated after 48 h in total excrements
for NOAC and 49 6 3% for ara-C. The cumulated radioactivity over
48 h gave a ratio between urine and feces of 32:1 for ara-C-treated
mice, whereas for animals receiving NOAC, the ratio was 2:1, indi-
cating the distinct differences in the excretion of the two compounds.
From the fit of the excretion data presented in Fig. 3, the extrapolated
time of quantitative and maximal excretion were calculated. Thus,
NOAC radioactivity would excrete to 60% of the injected dose in
urine within 43 h and to 54% in feces within 9 days. According to our
calculations, the excretion of ara-C should be completed after 12 h. As
comparison, Ho and Neil (1997) recovered only 58% of injected
radioactivity excreted after 1 week by mice for the lipophilic ara-C
derivative ara-C-59-palmitate. Representative HPLC chromatograms
of extracts of feces and urine are shown in Fig. 4A for mice treated
with NOAC and in Fig. 4B for ara-C, respectively. From NOAC-
treated mice, radioactivity was detected in the eluted void volumes of
urine and in the PBS feces extracts (pool I, Rt 4–6 min). Methanolic
feces extracts displayed three major tritium-containing peaks eluting
as pool I (Rt 4–6 min), pool II (Rt 8–10 min), and pool III (Rt 21–23
min). Pools I, II, and III of the methanolic feces extracts contained UV
active (l 5 279 nm) molecules (Fig. 4A). In the urine of ara-C-treated
mice, radioactivity was detected only in the void volume with a Rt of
4 to 6 min.
FIG. 4. Representative HPLC chromatograms (method a) of mouse excrements
collected between 8 to 24 h after NOAC (A) or 0 to 4 h after ara-C (B)
treatment.
In urine of ara-C- or NOAC-treated mice, ara-C and ara-U were identified by
LC/MS. NOAC- treated mice contained NOAC 1 OSO3H in pool I, NOAC 1 OH
in pool II, and NOAC in pool III.
TABLE 1
Distribution of radioactivity and metabolites identified in HPLC-purified extracts of urine and feces of mice
NOACa Ara-C
Urine Feces Urine Feces
Recovery in excrements (% of Dose)b 39 6 0.5 16 6 2 48 6 3 2 6 0.5
HPLCc Method a Method b Method a
Pool I Pool II Pool III
Rt (min) 4–5 5–8 4–6 8–10 21–23 4–5 5–8
Recovery in pools (% of Dose)d 25 6 0.3 11 6 0.1 8 6 0.7 4 6 0.5 2 6 0.1 33 6 2 13 6 1 NDe
Metabolitesf Ara-C Ara-U NOAC 1 OSO3H NOAC 1 OH NOAC Ara-C Ara-U
a Four mmol drug per mouse.
b Accumulated over 48 h. Calculated directly from urine or feces extracts. Mean of three experiments.
c HPLC methods are described in Materials and Methods. Rt, for retention time.
d Cumulated from pools indicated in Fig. 4, A and B.
e ND, not determined.
f Detected with LC/MS in corresponding pools.
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Mice receiving NOAC had the highest excretion rate of radioac-
tivity in all peaks detected by HPLC in urine and feces during the
collection interval of 8 to 24 h (Fig. 3). Pool I from feces contained
always more radioactivity than pools II or III. The highest ara-C
excretion occurred earlier between 0 to 8 h.
Identification of Metabolites. From LC/MS spectra of standards it
was found that NOAC and related substances like N4-hexyl-1-b-D-
arabinofuranosylcytosine and NHAC, produced the protonated mo-
lecular ion [M1H]1, the protonated dimer [(2 M)1H]1, and the
fragment M-arabinose termed [M91H]1 at a cone voltage of 42 V. By
running the standards under collision-activating conditions (cone volt-
age of 100 V), a signal for the [cytosine1H]1 moiety appeared in
addition to the other signals already detected with a cone voltage of 42
V. Under 1ESI conditions, sodium and potassium adducts could be
seen occasionally. From chromatography with HPLC method a, it was
known that NOAC standard eluted in pool III (Rt 21–23 min). Thus,
the HPLC pool III from liver and feces extracts were analyzed by
LC/MS (HPLC method c). These samples produced mass spectra
identical with those obtained with NOAC standard, with the identical
Rt of 33 min. The molecular masses and the spectra of NOAC and its
metabolites are shown in Table 2 and Fig. 5. In pool II obtained with
HPLC a (Rt of 8–10 min), MS signals differing from blank spectra
were detected at a Rt of 32 min with HPLC method c. These mass
spectra indicated a mass loss of 132 from m/z 512, which we presume
to correspond to a loss of arabinose by rearrangement. The same
neutral loss is observed with NOAC (Fig. 5A, m/z 496 to 364). The
loss of 18 from m/z 380 to m/z 362 is interpreted as the loss of water
and formation of a double bond. We conclude from these results and
from the shorter retention time compared with NOAC (LC/MS with
HPLC c) that the detected molecule might be hydroxylated NOAC
(Fig. 5B, NOAC 1 OH), with the hydroxyl group located most
probably on the alkyl chain (Szinai and De Clercq, 1989; Yoshida et
al., 1990; Boucher et al., 1996). However, it is not possible to assign
the exact position of hydroxylation on the alkyl chain of NOAC. More
information about the detected metabolites was obtained by running
the LC/MS system with a negative cone voltage. The absence of TFA
in the mobile phase of the HPLC method c allowed us to detect
negatively charged molecules. Increasing the pH of the mobile phase
resulted in a change of retention times for NOAC (Rt 36 min) and its
metabolites (see Table 2). The typical fragmentation patterns [M-H]2,
[M9-H]2, and [cytosine-H]2 were present again. The expected hy-
droxylated and sulfated metabolite (NOAC 1 OSO3H, Fig. 5C) in
pool I (Rt 4–6 min HPLC a) was not detected until running the MS
in negative ion mode at a cone voltage of 100 V. The mass spectrum
with a Rt of 30 min consisted of [M-H]2, [M9-H]2, and a signal of m/z
97 that could be attributed to HSO42, whereas m/z 80 corresponds to
the SO32-radical, a marker ion for sulfonates and sulfates (see Table
2). Going back to 1ESI conditions, the signal m/z 593 (Rt 28 min) was
detected with 42 V but not with 100 V. NOAC (Rt 36 min) and NOAC
1 OH (Rt 31 min) were also detected by 2ESI LC/MS. The com-
parison of all detected spectra with the corresponding blanks revealed
the existence of possible other metabolites in feces pools I and II of
HPLC a. However, the signals were not strong enough to draw any
conclusions regarding the structure of these metabolites.
Purified fractions from urine (Rt 4–5 min and 5–8 min, HPLC
method b) were analyzed with LC/MS (HPLC b), using cone voltages
of 15 V and 42 V. Furthermore, the scanned mass range was reduced
to 100 to 300 m/z to increase sensitivity. Applying this method, the
standards ara-C and ara-U displayed the typical pattern of [M1H]1
and [M91H]1, which is cytosine or uracil if M stands for ara-C or
ara-U, respectively. The LC/MS analysis of urine from ara-C-treated
mice after HPLC purification confirmed the existence of ara-C and
ara-U in the corresponding fractions, as summarized in Table 3. This
was also the case for urine of mice injected with NOAC, however with
a significantly weaker signal. Therefore, the ara-U signal at 115V
could not be detected. Analysis of the PBS feces extract under soft
ionization conditions (cone voltage 15V) gave no signals different
from blank. Thus, we conclude that the concentrations of metabolites
were too low for a signal to be detected.
Discussion
Because NOAC is insoluble in aqueous systems, the drug was
administered as liposomal formulation. From earlier investigations we
found that liposomal NOAC is transferred from the carrier after i.v.
application to erythrocytes and plasma proteins, mainly to the lipopro-
teins. The pharmacokinetic properties of NOAC were assessed with
ICR mice, resulting in elimination half-lives of injected radioactivity
from blood with 7 h and from the liver with 8 h (Koller-Lucae et al.,
TABLE 2
Summary of molecular weights of molecules and fragment ions detected with LC/MS in feces extract of NOAC-treated mice collected between 8 and 24 h
Pools Rta LC/MS Rtb Cone Voltage
Molecular Ions Fragmentation Loss of ArabinoseM9 5 M 2 132
[M 1 H]1 [2M 1 H]1 [M9 1 H]1 [(M9 2 H2O) 1 H]1 [Cytosine 1 H]1
min min V
NOAC III (21–23) 33.1 142 496.5 991.8 364.4c
33.1 1100 496.5 991.7 364.4 112.1
NOAC 1 OH II (8–10) 32.2 142 512.3 380.4 362.4
32.1 1100 511.9 362.4 112.0
NOAC 1 OSO3H I (4–6) 28.0 142 593.0
[M 2 H]2 [2M 2 H]2 [M9 2 H]2 HSO42 SO32.
NOAC III (21–23) 35.7 242 494.5 989.9
35.4 2100 494.5 989.8 362.4
NOAC 1 OH II (8–10) 31.4 242 510.5 378.9
NDd
NOAC 1 OSO3H I (4–6) 29.5 242 590.5 97.0
29.6 2100 590.5 458.4 97.0 80
a Rt of HPLC method a (for details see Materials and Methods) of feces extract purification.
b Rt of MS signal after passage through LC/MS system (method c).
c Strongest mass signals are indicated in italic letters.
d ND, Not determined.
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1997; Rentsch et al., 1995). In this study, metabolism and excretion of
NOAC were investigated. With the LC/MS analysis of purified liver
extracts (without gall bladder) only unmetabolized NOAC was de-
tected at all time points. More hydrophilic metabolites of NOAC were
expected to be found in the cytosol or in the methanolic liver extract.
Because we could not detect such metabolites, we assume that these
metabolites might be cleared from the liver at fast rates after their
formation or that they are present at undetectable concentrations. Low
amounts of radioactivity were measured in the liver cell cytosol,
eluting at the same Rt as standard NOAC. There, the lipophilic NOAC
is expected either to bind to proteins, e.g., to the fatty acid binding
protein (Storch et al., 1996), or to associate with the lipid droplets.
The radioactivity found in feces indicates that NOAC and possible
metabolites that were formed in the liver are probably excreted into
FIG. 5. Mass spectra of compounds detected in feces extracts of NOAC-treated mice.
LC/MS analyses were performed with HPLC method c and spectrum A (1ESI, cone voltage 100V), B (1ESI, cone voltage 42 V), and C (2ESI, cone voltage 100V)
were recorded from pools III, II, and I of feces extracts purified with HPLC method a. Rearrangements necessary for fragmentation are represented at top of figure. M*
stands for M-132, which is the loss of the arabinose moiety. Peaks in B and C marked with a cross are unidentified compounds.
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the gall bladder. This hypothesis is supported by Szinai and De Clercq
(1989) who found for a lipophilic deoxyuridine derivative and its
metabolites high concentrations in the gall bladder but only low
amounts in the liver.
The HPLC chromatogram (Fig. 4) of feces, which gave two peaks
different from NOAC and the appearance of 39% of the injected
radioactivity in the urine, demonstrates that NOAC is metabolized in
the mouse. A model for the metabolic pathway of NOAC is presented
in Fig. 6. Modification of the drug occurred within 4 h after applica-
tion as ara-C, and its typical metabolite ara-U already found in urine
in the first collecting interval (Fig. 3). This is in accordance with
earlier findings of NOAC radioactivity peaking in the kidneys 3 h
after i.v. application (Koller-Lucae et al., 1997).
It is conceivable that the formation of ara-C could take place by
oxidative dealkylation and cleavage of the C-N bond, producing ara-C
and the oxidized alkyl side chain (Testa and Jenner, 1976). As another
possibility, the complete b-oxidation of the NOAC alkyl chain in
analogy to fatty acid metabolism (Rognstad, 1995) as described for
related lipophilic drugs by Yoshida (Yoshida et al., 1990) and Oh-Ishi
(Oh-Ishi et al., 1981) could occur. The latter metabolic pathway could
be consistent with the finding of the necessary precursor molecule, the
hydroxylated NOAC 1 OH, which was detected in pool II of feces
extract eluted by HPLC method a (Rt 8–10 min). Thus, NOAC seems
to have several metabolic pathways, because, in addition to the
metabolites NOAC 1 OH and NOAC 1 OSO3H, the feces extract
contained other unidentified MS signals. An obvious pathway to
introduce a more hydrophilic group would consist in the sulfatation of
hydroxylated NOAC, occurring most probably at the introduced hy-
droxyl group of NOAC 1 OH by using the active sulfate in 39phos-
phoadenosyl-59-phosphosulfate. MS signals consistent with this hy-
pothesis (Fig. 5C) were found in pool I of the feces extract eluting
from HPLC a (Rt 4–6 min). The other signals in this pool that were
also different from corresponding blank spectra were not strong
enough to allow assignment to possible metabolites.
The high amounts of unmetabolized ara-C found in urine of mice
treated with ara-C or NOAC is not consistent with results from
humans in which 80% of ara-C is excreted as ara-U (Ho and Frei,
1971). The difficulty in comparing results obtained from different
species was reported by Dedrick and coworkers (Dedrick et al., 1973)
who found large differences in the deaminase activity for ara-C in
several tissues between humans and mice. Ho (1973) pointed out that
the deaminase activity in mice is half as efficient as in humans and
found 35% unmetabolized ara-C in urine 24 h after injection, which is
comparable with our findings. Mice treated with lipophilic behenoyl-
ara-C excreted about 14% of the administered radioactivity as ara-U
and 12% as ara-C (Oh-Ishi et al., 1981). In our study, NOAC was
excreted to 25% as ara-C and 11% as ara-U in urine. The high
percentages of ara-C and its metabolite ara-U found in NOAC treated
mice are surprising and demonstrate the difference in results from in
vitro experiments. Horber et al. (1995a) reported the formation of only
2% ara-U after in vitro incubation of the alkyl ara-C derivative
NHAC, which differs from NOAC only by two CH2 groups in the
alkyl chain, with human plasma, or with mouse liver microsomes. The
low amounts of ara-U formation after incubation with NHAC in vitro
was also consistent with the finding that only 2 to 5% ara-C-59-
triphosphate were generated in HL-60, K-562, or U-937 leukemia
cells (Horber et al., 1995a), which was 2.5 to 150 times less than
observed with ara-C. Furthermore, we found a very low affinity of
NOAC to deoxycytidine kinase, the key enzyme for ara-C phosphor-
ylation (data not shown). Additionally, NHAC induced apoptosis in
HL-60 cells only with concentrations 20 times higher than ara-C
(Horber et al., 1995c). Even though the in vitro studies showed
marked differences to ara-C, the cytotoxic effects of NHAC or NOAC
in K-567 and U-937 cells (Horber et al., 1995b) or in animal exper-
iments (Schwendener et al., 1995b; 1996) are comparable with or
even superior to ara-C. The formation of ara-C from NOAC might
have an additive effect on the antitumor activity of NOAC in mice.
The cell culture experiments proved that ara-C formation from NHAC
or NOAC is not essential for the cytotoxic effect of NOAC. Therefore,
besides the formation of ara-C, other, still unknown, mechanisms of
action might be important.
Summarizing our results, we found that NOAC is metabolized by
two major pathways, one leading to the hydrophilic metabolites ara-C
and ara-U and one in which NOAC is transformed into more hydro-
philic metabolites by hydroxylation and sulfatation of the lipophilic
alkyl side chain. In future studies we will analyze blood and urine of
NOAC-treated human patients for metabolites to elucidate to what
extent ara-C might contribute to the antitumor effect of NOAC.
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TABLE 3
Summary of retention times and molecular weights of molecules and fragment ions detected in urine of ara-C- (collecting interval 4 to 8 h) or NOAC- (collecting
interval 8 to 24 h) treated mice
Pools Rta LC/MS Rtb Cone Voltage Molecule peak Loss of arabinose
min min V [M 1 H]1 [Cytosine 1 H]1
Ara-C-treated mouse
Ara-C 4–5 4.4 15 244c 112
4.5 42 244 112
Ara-U 5–8 6.4 15 245 113
6.5 42 245 113
NOAC-treated mouse
Ara-C 4–5 4.6 15 244 112
4.5 42 244 112
Ara-U 5–8 5.4 15
5.4 42 245 113
a Rt of fractions prepared with HPLC b for LC/MS analysis.
b Rt from LC/MS system run with HPLC method b.
c Strongest mass signals are indicated in italic letters.
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FIG. 6. Suggested metabolic pathway of NOAC in mice.
Asterisk indicates position of tritium label.
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